You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 10, 2024

CLINICAL TRIALS PROFILE FOR LIALDA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Lialda

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00151892 ↗ Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis Completed Shire Phase 3 2005-04-08 Ulcerative colitis is a disease of the large bowel (colon) and rectum in which the lining of the bowel becomes red and swollen. Over time, patients with this disease may experience acute episodes of diarrhea, rectal bleeding and abdominal pain followed by periods of time without disease symptoms. 5-ASA drugs are a standard treatment for ulcerative colitis. Mesalazine is an experimental drug designed to gradually release 5-ASA into the areas of large bowel associated with ulcerative colitis. This study will test the safety and efficacy of mesalazine in keeping ulcerative colitis in remission.
NCT00446849 ↗ Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC) Completed Shire Phase 4 2007-05-01 To evaluate the percentage of subjects with clinical recurrence of UC at 6 months using MMX mesalamine once daily.
NCT00545103 ↗ Prevention of Recurrence of Diverticulitis Completed Shire Phase 3 2007-12-06 The purpose of this study is to determine whether SPD476 is effective in reducing recurrence of diverticulitis.
NCT00652145 ↗ Dose Escalation and Remission (DEAR) Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 4 2008-09-01 The proposed study will test whether increasing Lialda dose can reduce fecal calprotectin (FCP) levels, a marker of intestinal inflammation that is highly predictive of the risk of relapse among patients with quiescent ulcerative colitis. Sixty patients with FCP levels <50µg/g stool will be observed for 48 weeks. All patients will have FCP concentration measured using a commercially available assay at enrollment, 6 weeks and 12 weeks. All patients with persistently elevated FCP will receive one or both of the following interventions: change in the mesalamine formulation to Lialda and/or increase in the dose of Lialda. Reduction in FCP levels below 50µg/g stool 6 weeks after randomization will be the primary outcome. The proportion of patients achieving this outcome will be compared between groups using Fisher's exact test. All randomized patients as well as those who were excluded from the randomized trial because of a low FCP concentration at baseline will be followed to week 48 to determine the rate of clinical relapse.
NCT00652145 ↗ Dose Escalation and Remission (DEAR) Completed Shire Phase 4 2008-09-01 The proposed study will test whether increasing Lialda dose can reduce fecal calprotectin (FCP) levels, a marker of intestinal inflammation that is highly predictive of the risk of relapse among patients with quiescent ulcerative colitis. Sixty patients with FCP levels <50µg/g stool will be observed for 48 weeks. All patients will have FCP concentration measured using a commercially available assay at enrollment, 6 weeks and 12 weeks. All patients with persistently elevated FCP will receive one or both of the following interventions: change in the mesalamine formulation to Lialda and/or increase in the dose of Lialda. Reduction in FCP levels below 50µg/g stool 6 weeks after randomization will be the primary outcome. The proportion of patients achieving this outcome will be compared between groups using Fisher's exact test. All randomized patients as well as those who were excluded from the randomized trial because of a low FCP concentration at baseline will be followed to week 48 to determine the rate of clinical relapse.
NCT00652145 ↗ Dose Escalation and Remission (DEAR) Completed James Lewis Phase 4 2008-09-01 The proposed study will test whether increasing Lialda dose can reduce fecal calprotectin (FCP) levels, a marker of intestinal inflammation that is highly predictive of the risk of relapse among patients with quiescent ulcerative colitis. Sixty patients with FCP levels <50µg/g stool will be observed for 48 weeks. All patients will have FCP concentration measured using a commercially available assay at enrollment, 6 weeks and 12 weeks. All patients with persistently elevated FCP will receive one or both of the following interventions: change in the mesalamine formulation to Lialda and/or increase in the dose of Lialda. Reduction in FCP levels below 50µg/g stool 6 weeks after randomization will be the primary outcome. The proportion of patients achieving this outcome will be compared between groups using Fisher's exact test. All randomized patients as well as those who were excluded from the randomized trial because of a low FCP concentration at baseline will be followed to week 48 to determine the rate of clinical relapse.
NCT00751699 ↗ Pharmacokinetics of Asacol 2.4 g/Day and Lialda 2.4 g/Day in Healthy Volunteers Completed Warner Chilcott Phase 1 2007-03-01 This study evaluated pharmacokinetics of 5-ASA and N-Ac-5-ASA associated with each of 3 regimens of oral mesalamine 2.4 g/day (Lialda 2.4 g/day 2 x 1.2 g every 24 hours, Asacol® 6 x 400 mg every 24 hours, or Asacol 2 x 400 mg every 8 hours). Primary endpoints were 5-ASA area under the plasma concentration versus time curve from zero to 24 hours (AUC24) and total 5-ASA percent of dose excreted (A'e [%]) over the 24-hour period on Day 7.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lialda

Condition Name

Condition Name for Lialda
Intervention Trials
Ulcerative Colitis 6
Healthy 4
Colitis, Ulcerative 1
Diverticulitis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lialda
Intervention Trials
Colitis, Ulcerative 6
Ulcer 5
Colitis 5
Irritable Bowel Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lialda

Trials by Country

Trials by Country for Lialda
Location Trials
United States 105
Canada 13
India 11
South Africa 9
Brazil 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lialda
Location Trials
Florida 7
Pennsylvania 5
Maryland 5
Kansas 5
Texas 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lialda

Clinical Trial Phase

Clinical Trial Phase for Lialda
Clinical Trial Phase Trials
Phase 4 3
Phase 3 4
Phase 2 1
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lialda
Clinical Trial Phase Trials
Completed 12
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lialda

Sponsor Name

Sponsor Name for Lialda
Sponsor Trials
Shire 9
Warner Chilcott 1
Shire Human Genetic Therapies, Inc. 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lialda
Sponsor Trials
Industry 11
Other 4
NIH 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.